Belite Bio Earnings Call Transcripts
Fiscal Year 2026
-
Tinlarebant, an oral therapy for Stargardt disease, achieved a 36% reduction in lesion growth and sustained 80% RBP4 reduction in phase III trials, with strong safety and regulatory progress. The therapy addresses a major unmet need and is positioned for broad application in retinal diseases.
-
Tinlarebant, an oral RBP4 antagonist, showed a 36% reduction in Stargardt disease progression in a global phase III trial, with strong safety and efficacy in both eyes. U.S. and global regulatory filings are underway, and commercialization plans focus on genetic testing and market readiness.
Fiscal Year 2025
-
Key 2025 milestones included positive phase III results for Stargardt disease, strong fundraising, and a robust cash position. NDA submission is planned for Q2 2026, with commercialization targeted for Q1 2027 and significant investments in launch preparation.
-
The phase III DRAGON Study showed Tinlarebant significantly slowed Stargardt disease progression by 36% in adolescents, with robust efficacy in both eyes and a strong safety profile. Regulatory agencies support the primary endpoint, and the therapy is expected to benefit a broad patient population.
-
Phase 3 trials for GA and Stargardt disease advanced, with global regulatory submissions planned for 2026. Q3 saw increased R&D and G&A expenses, a net loss of $21.7M, and a strong cash position of $275.6M after major financings.
-
Tinlarebant, an oral therapy for Stargardt disease and geographic atrophy, is advancing through multiple phase III trials, with top-line data from the DRAGON study expected soon. Interim results show significant efficacy and safety, supporting regulatory designations and a strong market opportunity.
-
Tinlarebant’s pivotal DRAGON trial in Stargardt disease is nearing top-line data, with NDA submission targeted for H1 2026. The drug has shown strong safety and efficacy signals, received FDA breakthrough designation, and is positioned for broad market entry, supported by robust financials and patent protection.
-
Tinlarebant, an oral therapy for Stargardt disease and GA, has shown promising efficacy and safety in phase 2 and 3 trials, with regulatory momentum including FDA Breakthrough Therapy Designation. The company is preparing for global filings, commercialization, and further GA development, supported by a strong financial runway.
-
Tinlarebant, a once-daily oral therapy, is advancing through late-stage trials for Stargardt disease and geographic atrophy, showing promising safety and efficacy in slowing lesion growth. Regulatory designations and strong patent protection support its potential as a first-in-class treatment.
-
Tinlarebant advanced in global phase three trials for Stargardt’s disease and geographic atrophy, with strong regulatory momentum and a four-year cash runway. Q2 net loss widened due to higher R&D and G&A expenses, mainly from share-based compensation.
-
Tinlarebant, an oral therapy targeting Stargardt disease and geographic atrophy, is advancing through multiple phase III trials with promising interim efficacy and safety data. The program has received breakthrough and orphan designations, with key readouts expected by year-end and in 2027.
-
Tinlarebant, an oral therapy for Stargardt disease and dry AMD, has received FDA breakthrough designation following strong interim phase III data. With over 50,000 potential U.S. patients and sufficient capital, the company is advancing global regulatory submissions and expects final data by year-end.
-
Tinlarebant, an oral therapy for Stargardt disease and GA, showed strong safety and efficacy in phase 2 and 3 trials, with regulatory submission underway and approval targeted for 2026. The company has a four-year cash runway and expects profitability, especially as GA market potential is realized.
-
Tinlarebant clinical trials advanced with strong interim results and regulatory support, while Q1 2025 saw increased R&D and G&A expenses mainly from non-cash share-based compensation. Cash reserves of $157.4M provide a four-year runway to complete all trials.
-
Tinlarebant, an oral therapy for Stargardt disease and geographic atrophy, has shown a 50% reduction in lesion growth and strong safety in phase II and interim phase III data. Regulatory agencies outside the U.S. may approve based on a single study, with final data expected by Q1 2026.
-
The phase III DRAGON trial interim analysis showed Tinlarebant stabilized visual acuity and was well tolerated in adolescent Stargardt disease. DSMB recommended submitting data for regulatory review, with trial completion on track for Q4 2025 and topline data expected in early 2026.
Fiscal Year 2024
-
Tinlarebant advanced in global phase III trials for Stargardt disease and GA, with strong interim safety and efficacy data prompting regulatory submission. Financials show increased R&D and G&A expenses, a $36.1M net loss, and a four-year cash runway supported by a recent $15M capital raise.
-
Advanced Tinlarebant clinical trials for Stargardt disease and GA, with strong safety and efficacy signals and a robust cash position supporting four years of operations. Phase III enrollment and interim analyses are progressing, with regulatory designations highlighting unmet needs.
-
Tinlarebant, an oral therapy targeting vitamin A delivery, showed promising safety and efficacy in adolescent Stargardt's disease, with stabilized vision and reduced lesion growth. Phase III trials in Stargardt's and geographic atrophy are underway, with key data expected from late 2024 through 2027.
-
The company is advancing Tinlarebant, an oral therapy for Stargardt disease and GA, showing promising phase II results with reduced lesion growth and stabilized vision. Phase III trials are ongoing, with regulatory momentum and a differentiated mechanism targeting early disease.
-
Tinlarebant, an oral therapy for Stargardt disease and geographic atrophy, is advancing through global phase III trials with strong safety and efficacy signals. Key milestones include interim data in late 2024/early 2025 and robust patent and financial positions.
-
Tinlarebant, an oral RBP4 antagonist, is advancing through phase III trials for Stargardt disease and geographic atrophy, showing strong efficacy and safety in early studies. The drug’s mechanism targets toxic vitamin A byproducts, with potential for early approval in Japan and significant market impact.
-
Tinlarebant clinical trials advanced with key regulatory designations and strong financial backing, including $112 million in cash and a recent $25 million raise. Interim phase 3 data is expected by early 2025, with ongoing global trials addressing significant unmet needs.